Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 28;24(1):1531.
doi: 10.4102/sajhivmed.v24i1.1531. eCollection 2023.

Dolutegravir resistance in three pregnant and breastfeeding women in South Africa

Ninke Fourie  1 , Kate Rees  1   2 , Denis Mali  3 , Bridget Mugisa  3 , Cara O'Connor  1 , Natasha Davies  1
Affiliations

Dolutegravir resistance in three pregnant and breastfeeding women in South Africa

Ninke Fourie et al. South Afr J HIV Med. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.

Figures

FIGURE 1
FIGURE 1
Summary of the HIV viral load, CD4 count and antiretroviral therapy timeline for each case. (a) Case 1. (b) Case 2. (c) Case 3.
See this image and copyright information in PMC

References

    1. World Health Organization . Update of recommendations on first- and second-line antiretroviral regimens [homepage on the Internet]. Geneva; 2019. [cited 2023 Aug 07]. Available from: https://www.who.int/publications/i/item/WHO-CDS-HIV-19.15
    1. Kanters S, Vitoria M, Zoratti M, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. EClinicalMedicine. 2020;28:100573. 10.1016/j.eclinm.2020.100573 - DOI - PMC - PubMed
    1. Kufa T. Dolutegravir in late pregnancy: Where to from here? Lancet HIV. 2022;9(8):e522–e523. 10.1016/S2352-3018(22)00193-X - DOI - PubMed
    1. Paton NI, Musaazi J, Kityo C, et al. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): Week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. Lancet HIV. 2022;9(6):e381–e393. - PubMed
    1. Zhao Y, Keene C, Griesel R, et al. AntiRetroviral therapy in second-line: Investigating Tenofovir-lamivudine-dolutegravir (ARTIST): Protocol for a randomised controlled trial. Wellcome Open Res. 2021;6:33. 10.12688/wellcomeopenres.16597.1 - DOI - PMC - PubMed

LinkOut - more resources